文献速递血栓与止血

TQB3473新型脾酪氨酸激酶抑制剂治疗原发免疫性血小板减少症的单臂开放标签多中心1期研究

TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study.
PubMed 文献 · J Thromb Haemost · 2026-04-15

该1期研究纳入中国6中心18-75岁复发/难治性原发免疫性血小板减少症患者,口服TQB3473 400/600/800 mg每日一次共24周。总缓解率56.8%,600 mg组持久缓解率25%,治疗相关不良事件多为1-2级,推荐2期剂量为600 mg每日一次。

要点

  • TQB3473总缓解率56.8%,600 mg和800 mg组分别为60.7%和66.7%。
  • 600 mg组持久缓解率为25%,推荐2期剂量为600 mg每日一次。
  • 治疗相关不良事件发生率72.9%,多为1-2级,无血栓事件或死亡。

核心结论

  • TQB3473在复发/难治性ITP中显示有前景的疗效和有利的安全性,支持600 mg每日一次作为推荐2期剂量。

研究设计与样本

  • 单臂、开放标签、多中心1期研究,纳入中国6中心18-75岁复发/难治性ITP患者。
  • 患者接受口服TQB3473 400、600或800 mg每日一次,持续24周,包括剂量递增和扩展阶段。
  • 主要终点为安全性和确定推荐2期剂量。

主要发现

  • 总缓解率(12周内至少一次血小板计数≥50×10^9/L)为56.8%。
  • 缓解率:400 mg组0%,600 mg组60.7%,800 mg组66.7%。
  • 600 mg组持久缓解率(14-24周内最后6次访视中至少4次血小板计数≥50×10^9/L)为25%。
  • 治疗相关不良事件发生率72.9%,多为1-2级。
  • 600 mg队列最常见治疗相关不良事件:乳酸脱氢酶升高32.1%、天冬氨酸氨基转移酶升高28.6%、丙氨酸氨基转移酶升高25.0%、高甘油三酯血症21.4%。

关键数值与推荐

  • 总缓解率定义为12周内至少一次血小板计数≥50×10^9/L。
  • 持久缓解率定义为14-24周内最后6次访视中至少4次血小板计数≥50×10^9/L。
  • 基于有利的获益-风险特征(包括更长的缓解持续时间和更好的耐受性),确定600 mg每日一次为推荐2期剂量。

临床怎么用

  • 对于复发/难治性ITP,TQB3473 600 mg每日一次可作为潜在新治疗选择,目前正在3期试验中评估。

局限性

  • 本研究为单臂、开放标签1期研究,样本量未在原文中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective treatments for relapsed/refractory immune thrombocytopenia (ITP) remain limited. OBJECTIVES: TQB3473, a novel oral spleen tyrosine kinase inhibitor, was evaluated to address this unmet need. METHODS: This phase 1 study enrolled patients aged 18 to 75 years with relapsed/refractory ITP from 6 centers in China. Patients received oral TQB3473 (400, 600, or 800 mg once daily) for 24 weeks during the dose escalation and expansion phases. The primary endpoints were safety and determination of the recommended phase 2 dose. RESULTS: The overall response rate (platelet count ≥ 50 × 109/L at least once within 12 weeks) was 56.8%. Response rates were 0% (400 mg), 60.7% (600 mg), and 66.7% (800 mg). The durable response rate (platelet count ≥ 50 × 109/L in ≥4 of the last 6 visits within 14-24 weeks) was 25% with a 600 mg dose. Treatment-related adverse events occurred in 72.9% of patients and were mostly grade 1 to 2. The most frequent treatment-related adverse events in the 600 mg cohort were increased lactate dehydrogenase (32.1%), increased aspartate aminotransferase (28.6%), increased alanine aminotransferase (25.0%), and hypertriglyceridemia (21.4%). Hypertension (3.6%) and gastrointestinal toxicity were infrequent. No thrombotic events or deaths were reported. Based on a favorable benefit-risk profile, including a longer response duration and better tolerability, 600 mg once daily was established as the recommended phase 2 dose. CONCLUSION: The promising efficacy and favorable safety profile of TQB3473, particularly its minimal hypertension and gastrointestinal toxicity, support 600 mg once daily as the recommended dose and underscore its potential as a new treatment option for relapsed/refractory ITP, a premise currently under evaluation in a phase 3 trial.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ding B, Gong T, Du X, et al. TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study. J Thromb Haemost. 2026. PMID: 41997562. doi:10.1016/j.jtha.2026.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。